Cohance Lifesciences reported Q1 FY27 results with revenue at ₹422.3 crore and adjusted EBITDA at ₹9.2 crore. The company cited shipment phasing and agrochemical softness, expecting a return to YoY growth in H2 FY27.
Cohance Lifesciences Reports Q1 FY27 Results
Consolidated Revenue: ₹422.3 crore Consolidated Adjusted EBITDA: ₹9.2 crore Reader Takeaway: Stable standalone business faces near-term pressure from subsidiary losses and agrochemical segment weakness. ## What just happened Cohance Lifesciences posted its financial results for the first quarter of FY27. The company reported consolidated revenue of ₹422.3 crore and consolidated adjusted EBITDA of ₹9.2 crore. Performance was impacted by shipment phasing and a soft agrochemical segment. ## Why this matters The results indicate a challenging start to the fiscal year. While the standalone business showed resilience with revenue of ₹359.9 crore and adjusted EBITDA of ₹33.2 crore, the consolidated figures were pulled down by the loss-making NJ Bio subsidiary, which reported a negative EBITDA of ₹32.8 crore on revenue of ₹35.0 crore. ## The backstory The company's performance in Q1 FY27 is a continuation of certain pressures. The NJ Bio subsidiary has consistently weighed on overall profitability. Agrochemical demand is also known to be seasonal, typically picking up in the latter half of the fiscal year. ## What changes now Management expects sequential improvement from Q2 FY27 onwards, with a return to year-on-year growth projected for the second half of FY27. This outlook is based on scheduled commercial program deliveries and restocking. ## Risks to watch Key risks include the 5 observations received from the USFDA at the Pashamylaram facility, although management stated they do not relate to data integrity. The ongoing losses from NJ Bio and the recovery in the agrochemical segment remain critical watch points. ## Peer comparison (No verified peer comparison data available in the filing.) ## Context metrics Capital Expenditure for the quarter stood at ₹59.8 crore, and the company maintained a consolidated net cash position of ₹251.2 crore. ## What to track next Investors should monitor the resolution of USFDA observations, the turnaround strategy for NJ Bio, and the performance trajectory in the second half of FY27.
